1-8 of 8
Dimiter S. Dimitrov
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma

Peter M. Sullivan, Rajesh Kumar, Wei Li, Virginia Hoglund, Lingyan Wang, Yue Zhang, Megan Shi, Dusan Beak, Adam Cheuk, Michael C. Jensen, Javed Khan, Dimiter S. Dimitrov, Rimas J. Orentas
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (10): 1608–1621.
https://doi.org/10.1158/1535-7163.MCT-22-0059
Published: 07 October 2022
View article titled, FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma
Open the PDF for FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma in another window
Includes: Supplementary data
Journal Articles

Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization

Samantha Buongervino, Maria V. Lane, Emily Garrigan, Doncho V. Zhelev, Dimiter S. Dimitrov, Kristopher R. Bosse
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (11): 2228–2239.
https://doi.org/10.1158/1535-7163.MCT-20-1034
Published: 01 November 2021
View article titled, Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization
Open the PDF for Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization in another window
Journal Articles

A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface

Zhewei Tang, Mingqian Feng, Wei Gao, Yen Phung, Weizao Chen, Amit Chaudhary, Brad St. Croix, Min Qian, Dimiter S. Dimitrov, Mitchell Ho
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (4): 416–426.
https://doi.org/10.1158/1535-7163.MCT-12-0731
Published: 08 April 2013
View article titled, A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface
Open the PDF for A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface in another window
Includes: Supplementary data
Journal Articles

Human Monoclonal Antibodies Targeting Nonoverlapping Epitopes on Insulin-like Growth Factor II as a Novel Type of Candidate Cancer Therapeutics

Weizao Chen, Yang Feng, Qi Zhao, Zhongyu Zhu, Dimiter S. Dimitrov
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (7): 1400–1410.
https://doi.org/10.1158/1535-7163.MCT-12-0172
Published: 05 July 2012
View article titled, Human Monoclonal Antibodies Targeting Nonoverlapping Epitopes on Insulin-like Growth Factor II as a Novel Type of Candidate Cancer Therapeutics
Open the PDF for Human Monoclonal Antibodies Targeting Nonoverlapping Epitopes on Insulin-like Growth Factor II as a Novel Type of Candidate Cancer Therapeutics in another window
Includes: Supplementary data
Journal Articles

Human Monoclonal Antibody Fragments Binding to Insulin-like Growth Factors I and II with Picomolar Affinity

Qi Zhao, Yang Feng, Zhongyu Zhu, Dimiter S. Dimitrov
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (9): 1677–1685.
https://doi.org/10.1158/1535-7163.MCT-11-0281
Published: 07 September 2011
View article titled, Human Monoclonal Antibody Fragments Binding to Insulin-like Growth Factors I and II with Picomolar Affinity
Open the PDF for Human Monoclonal Antibody Fragments Binding to Insulin-like Growth Factors I and II with Picomolar Affinity in another window
Includes: Supplementary data
Journal Articles

Abstract B129: Preclinical assessment of targeting insulin‐like growth factor‐2 in bone metastasis from prostate cancer by a human neutralizing antibody (m610) and human adult bone implanted model

Taichi Kimura, Takeshi Kuwata, Satoshi Ashimine, Kanji Nagai, Yang Feng, Dimiter S. Dimitrov, Seiichi Saito, Atsushi Ochiai
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B129.
https://doi.org/10.1158/1535-7163.TARG-09-B129
Published: 10 December 2009
View article titled, Abstract B129: Preclinical assessment of targeting insulin‐like growth factor‐2 in bone metastasis from prostate cancer by a human neutralizing antibody (m610) and human adult bone implanted model
Journal Articles

A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity

Yang Feng, Xiaodong Xiao, Zhongyu Zhu, Emily Streaker, Mitchell Ho, Ira Pastan, Dimiter S. Dimitrov
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (5): 1113–1118.
https://doi.org/10.1158/1535-7163.MCT-08-0945
Published: 13 May 2009
View article titled, A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity
Open the PDF for A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity in another window
Journal Articles

Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function

Yang Feng, Zhongyu Zhu, Xiaodong Xiao, Vidita Choudhry, J. Carl Barrett, Dimiter S. Dimitrov
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (1): 114–120.
https://doi.org/10.1158/1535-7163.MCT-05-0252
Published: 23 January 2006
View article titled, Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function
Open the PDF for Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function in another window